Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema

PURPOSE: Intravitreal anti-vascular endothelial growth factor (VEGF) agents are effective in the treatment of central involving diabetic macular oedema (DMO). Vitreoretinal interface abnormalities (VRIA) are common in patients with DMO, and the effect of these on the response to anti-VEGF treatment...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Graefes Arch Clin Exp Ophthalmol
Hlavní autoři: Wong, Yun, Steel, David H. W., Habib, Maged S., Stubbing-Moore, Alex, Bajwa, Dalvir, Avery, Peter J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2016
Témata:
Retinal Disorders
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5364245/
https://ncbi.nlm.nih.gov/pubmed/27957600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00417-016-3562-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky